Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Journal of Transfusion Medicine
MENU
Shortcuts Submit an article Author Guidelines Reviewers 2020

open access

Vol 11, No 2 (2018)
Research paper
Published online: 2018-09-07
View PDF (polish) Download PDF file
Get Citation

Performance evaluation of cobas MPX test on cobas 6800 and cobas p 680 (Roche) for automatic testing of blood donors for RNA of hepatitis C virus (HCV), RNA human immunodeficiency virus (HIV) and DNA of hepatitis B virus (HBV)

Aneta Kopacz, Dorota Kubicka-Russel, Grzegorz Liszewski, Paulina Zwolińska, Ewa Sulkowska, Magdalena Łętowska, Piotr Grabarczyk
Journal of Transfusion Medicine 2018;11(2):39-51.

open access

Vol 11, No 2 (2018)
ORIGINAL PAPERS
Published online: 2018-09-07

Abstract

Background. The cobas MPX test for use with the cobas 6800 System is a qualitative, real-time PCR test for the detection of HIV-1 Groups M and O RNA, HIV-2 RNA, HCV RNA and HBV DNA in human plasma and serum. The test simultaneously identifies HIV, HCV and HBV (multiplex). Optional component to the cobas 6800 System is the cobas p 680 instrument that creates pools from individual samples. Aim. To evaluate the cobas MPX test in individual donations and in plasma pools using the cobas p 680 instrument. Material and methods. Analytical sensitivity was assessed with serial dilutions of the WHO International Standards (IS): HCV, HIV-1, HIV-2, HBV and Performance Panel HIV-1 (O) (Sera Care). Correct identification of reactive donations was evaluated by testing 473 negative and 7 reactive donations in minipools (≤ MP6). Results. Limits of detection (with 95% confidence limits) of cobas MPX were 7.12 IU/mL (4.40–15.62), and 31.33 IU/mL (17.84–76.80) for HCV and HIV-1, respectively. For HBV it was related to dilutions used for Probit analysis and equaled 3.97 IU/mL (2.25–9.75): 1,33 IU/mL (0,89–4,25); 2,05 IU/mL (1.45–3.40). All dilutions of the HIV-1 group O (100–10 copies/mL) and HIV-2 (31.6–10 IU/mL) samples were detected. Results of MPX tests imitating blood screening with the cobas6800 system were in accordance with expected results. Overall, false reactive rates for pooled samples were 0.1%. Conclusions. The cobas MPX test on the cobas 6800 System, including the cobas p 680 instrument demonstrated high sensitivity and satisfactory specificity required in Polish blood donation system. The cobas MPX test correctly identified infected donations without a significant risk of false results.

Abstract

Background. The cobas MPX test for use with the cobas 6800 System is a qualitative, real-time PCR test for the detection of HIV-1 Groups M and O RNA, HIV-2 RNA, HCV RNA and HBV DNA in human plasma and serum. The test simultaneously identifies HIV, HCV and HBV (multiplex). Optional component to the cobas 6800 System is the cobas p 680 instrument that creates pools from individual samples. Aim. To evaluate the cobas MPX test in individual donations and in plasma pools using the cobas p 680 instrument. Material and methods. Analytical sensitivity was assessed with serial dilutions of the WHO International Standards (IS): HCV, HIV-1, HIV-2, HBV and Performance Panel HIV-1 (O) (Sera Care). Correct identification of reactive donations was evaluated by testing 473 negative and 7 reactive donations in minipools (≤ MP6). Results. Limits of detection (with 95% confidence limits) of cobas MPX were 7.12 IU/mL (4.40–15.62), and 31.33 IU/mL (17.84–76.80) for HCV and HIV-1, respectively. For HBV it was related to dilutions used for Probit analysis and equaled 3.97 IU/mL (2.25–9.75): 1,33 IU/mL (0,89–4,25); 2,05 IU/mL (1.45–3.40). All dilutions of the HIV-1 group O (100–10 copies/mL) and HIV-2 (31.6–10 IU/mL) samples were detected. Results of MPX tests imitating blood screening with the cobas6800 system were in accordance with expected results. Overall, false reactive rates for pooled samples were 0.1%. Conclusions. The cobas MPX test on the cobas 6800 System, including the cobas p 680 instrument demonstrated high sensitivity and satisfactory specificity required in Polish blood donation system. The cobas MPX test correctly identified infected donations without a significant risk of false results.

Full Text:

View PDF (polish) Download PDF file
Get Citation

Keywords

RNA HCV; DNA HBV; RNA HIV; blood donation screening

About this article
Title

Performance evaluation of cobas MPX test on cobas 6800 and cobas p 680 (Roche) for automatic testing of blood donors for RNA of hepatitis C virus (HCV), RNA human immunodeficiency virus (HIV) and DNA of hepatitis B virus (HBV)

Journal

Journal of Transfusion Medicine

Issue

Vol 11, No 2 (2018)

Article type

Research paper

Pages

39-51

Published online

2018-09-07

Bibliographic record

Journal of Transfusion Medicine 2018;11(2):39-51.

Keywords

RNA HCV
DNA HBV
RNA HIV
blood donation screening

Authors

Aneta Kopacz
Dorota Kubicka-Russel
Grzegorz Liszewski
Paulina Zwolińska
Ewa Sulkowska
Magdalena Łętowska
Piotr Grabarczyk

References (16)
  1. Obwieszczenie Ministra Zdrowia z dnia 9 czerwca 2017 r. w sprawie wymagań dobrej praktyki pobierania krwi i jej składników, badania, preparatyki, przechowywania, wydawania i transportu dla jednostek organizacyjnych publicznej służby krwi. (Dz. Urz. Min. Zdr. 2017.63).
  2. Roche, cobas MPX, Roche Molecular Systems, Inc. , Branchburg New Jersey. ; 2015.
  3. Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline-Second Edition EP17-1 2012, v32, No. ; 8: 24.
  4. Manak M, Sina S, Anekella B, et al. Pilot studies for development of an HIV subtype panel for surveillance of global diversity. AIDS Res Hum Retroviruses. 2012; 28(6): 594–606.
    CrossRefPubMed
  5. Grabarczyk P, Kopacz A, Liszewski G, et al. Evaluation and performance characterization of TaqScreen MPX version 2.0 intended for HCV RNA, HIV RNA and HBV DNA screening in blood donors. American Association of Blood Banks Annual Meeting, Boston 06-09. ; 10: 2012.
  6. Guide to the preparation, use and quality assurance of blood components. Recommendation No. R (95) 15, 18th Edition, European Directorate for the Quality of Medicines & HealthCare. Strasbourg. : France.
  7. Grabarczyk P, Kopacz A, Liszewski G, et al. Polish Blood Service Viral Study Group. Effectiveness of various mini pool NAT systems for HBV detection in blood donors. Transfusion. 2009; 49(7): 1494–1495.
  8. Grabarczyk P, van Drimmelen H, Kopacz A, et al. Head-to-head comparison of two transcription-mediated amplification assay versions for detection of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus Type 1 in blood donors. Transfusion. 2013; 53(10 Pt 2): 2512–2524.
    CrossRefPubMed
  9. Ha J, Park Y, Kim HS. Evaluation of clinical sensitivity and specificity of hepatitis B virus (HBV), hepatitis C virus, and human immunodeficiency Virus-1 by cobas MPX: Detection of occult HBV infection in an HBV-endemic area. J Clin Virol. 2017; 96: 60–63.
    CrossRefPubMed
  10. Brojer E, Gronowska A, Medyńska J, et al. The hepatitis C virus genotype and subtype frequency in hepatitis C virus RNA-positive, hepatitis C virus antibody-negative blood donors identified in the nucleic acid test screening program in Poland. Transfusion. 2004; 44(12): 1706–1710.
    CrossRefPubMed
  11. Brojer E, Grabarczyk P, Liszewski G, et al. Polish Blood Transfusion Service Viral Study Group. Characterization of HBV DNA+/HBsAg- blood donors in Poland identified by triplex NAT. Hepatology. 2006; 44(6): 1666–1674.
    CrossRefPubMed
  12. Grabarczyk P, Kopacz A, Sulkowska E, et al. Blood donors screening for blood born viruses in Poland. Przegl Epidemiol. 2015; 69(3): 473–7, 591.
    PubMed
  13. Nübling CM, Heiden M, Chudy M, et al. Experience of mandatory nucleic acid test (NAT) screening across all blood organizations in Germany: NAT yield versus breakthrough transmissions. Transfusion. 2009; 49(9): 1850–1858.
    CrossRefPubMed
  14. Schmidt M, Korn K, Nübling CM, et al. First transmission of human immunodeficiency virus Type 1 by a cellular blood product after mandatory nucleic acid screening in Germany. Transfusion. 2009; 49(9): 1836–1844.
    CrossRefPubMed
  15. Müller B, Nübling CM, Kress J, et al. How safe is safe: new human immunodeficiency virus Type 1 variants missed by nucleic acid testing. Transfusion. 2013; 53(10 Pt 2): 2422–2430.
    CrossRefPubMed
  16. Chudy M, Weber-Schehl M, Pichl L, et al. Blood screening nucleic acid amplification tests for human immunodeficiency virus Type 1 may require two different amplification targets. Transfusion. 2012; 52(2): 431–439.
    CrossRefPubMed

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Journal of Transfusion Medicine dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl